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The WHO guidelines on evaluating similar biotherapeutic products (SBPs) were adopted by the Expert
Committee on Biological Standardization in 2009. The fundamental messages of the guidelines are that
a) generic approach is not suitable for licensing SBPs, b) only products that have been subjected to
a comparability exercise and show similarity to the reference biotherapeutic product (RBP) in terms of
their quality, safety and efﬁcacy are deﬁned as SBPs, and c) the products that are not shown to be similar
to the originator products as indicated in the guidelines should neither be described as "similar" nor
called SBPs. In view of these, the products which have not been subjected to a head to head comparison
with the RBP should be referred to as another term, e.g. ‘non-innovator’ therapeutic products.
In order to review the current situation in each country, a survey was planned in line with the
implementation workshop of the guidelines in August 2010. The results show that the diversity of
regulatory framework for licensing SBPs and the ambiguous use of the terms, ‘similar’ or ‘generic’,
present considerable challenges for the future use of SBPs.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
It is recognized that submission of reduced data packages may
be appropriate for licensing SBPs based on their similarity to RBPs.
While this is a truly attractive point to manufacturers who plan to
develop SBPs, providing assurance of the quality, safety and efﬁcacy
of SBPs by showing similarity to the RBP in a comparative manner
based on the given amount of data generated is not easy. This
causes much concern to not only manufacturers, but also to regu-
lators who have to be assured that the products are not only efﬁ-
cacious but also have a comparable safety proﬁle as the RBP. As
a result of evolving needs, several countries have established or are
developing their regulatory pathways for licensure of SBPs.
However, it is clear that the regulatory frameworks of countries are
diverse. These different requirements for licensing SBPs are
impacting on the future use of SBPs. In order to identify the current
diversity in approaches in different countries on evaluating SBPs for
the purpose of licensing, a questionnaire (Appendix) wass used in the WHO guidelines
ars’, ‘follow-on protein prod-
urisdictions.
ll rights reserved. The World Healthdeveloped one month prior to the ﬁrst WHO workshop on imple-
menting WHO guidelines on evaluating SBPs.
2. Questionnaire
The questionnaire was composed of six questions to evaluate
the current situation in each country, such as the legislative basis of
biotherapeutic products and SBPs (question 1), terminology issue
regarding SBPs (question 2), current status for licensing SBPs
(question 3), issues relating to RBPs (question 4), comparability
exercise in quality, non-clinical, and clinical studies (question 5),
and capacity of the regulatory authority for evaluating SBPs
(question 6) (see Appendix). In total, 13 representatives (partici-
pants in the implementation workshop) from different countries,
i.e. Brazil, Canada, People’s Republic of China (China), Cuba, India,
Iran, Japan, Jordan, Republic of Korea (Korea), Malaysia, Singapore,
Thailand, and United Kingdom of Great Britain and Northern
Ireland (UK) returned their responses.
3. Results
The responses to the questionnaire clearly show that there are
distinct differences among countries. The summary of results from
the survey is as follows, and more details about each country are
included in other articles in this issue of Biologicals.Organization has granted the Publisher permission for the reproduction of this article.
Table 1
Similar biological medicinal products approved in EU.
Product Company INN Reference Product Date Approved
Omnitrope Sandoz (owned by Novartis) Somatropin Genotropin (Pﬁzer) April 2006
Valtropin BioPartners Somatropin Humatrope (Eli Lilly) April 2006
Binocrit Sandoz Epoetin alfa Eprex/Erypo (Janssen-Cilag) August 2007
Epoetin alfa Hexal Hexal Biotech (owned by Novartis) Epoetin alfa Eprex/Erypo (Janssen-Cilag) August 2007
Abseamed Medice Arzneimittel Epoetin alfa Eprex/Erypo (Janssen-Cilag) August 2007
Silapo Stada Arzneimittel Epoetin zeta Eprex/Erypo (Janssen-Cilag) December 2007
Retacrit Hospira Epoetin zeta Eprex/Erypo (Janssen-Cilag) December 2007
Ratiograstim Ratiopharm Filgrastim Neupogen (Amgen) September 2008
Filgrastim Ratiopharm Ratiopharm Filgrastim Neupogen (Amgen) September 2008
Biograstim CT Arzneimittel Filgrastim Neupogen (Amgen) September 2008
Tevagrastim Teva Generics Filgrastim Neupogen (Amgen) September 2008
Zarzio Sandoz Filgrastim Neupogen (Amgen) February 2009
Filgrastim Hexal Hexal Biotech Forschungs GmbH Filgrastim Neupogen (Amgen) February 2009
Nivestim Hospira Filgrastim Neupogen (Amgen) 2010
Table 2
Acceptable countries/areas for RBP selection.
Countries Acceptable reference countries/areas
Brazil None (requires RBP licensed in Brazil)a
Canada licensed in ICH regions, e.g. USA, EU, Japan
China licensed in USA, EU
Cuba licensed in UAE, EU, Japan, Australia, Canada Iceland,
Norway, New Zealand, or Switzerland
Iran licensed in USA, EU, Australia
Japan None (requires RBP licensed in Japan)
Korea None (requires RBP licensed in Korea)a
Malaysia licensed in Australia, Canada, EU (centralized), UK, France,
Sweden, Japan, Switzerland, USA
Singapore None (requires RBP licensed in Singapore)
EU None (requires RBP licensed in EU)
EU: European Union; UAE: United Arab Emirates; UK: United Kingdom of Great
Britain and Northern Ireland; USA: United States of America.
a In cases where candidate RBPs that are already licensed in some countries are
not available in their markets, the same products (i.e. from the same manufacturing
site and the same production methods) can be allowed for use in comparability
studies.
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In countries participating in the survey, biotherapeutic products
have been regulated as one of the categories of biological products,
and therefore there is no speciﬁed regulation for the biotheraputic
products. Most countries have issued (e.g. Canada, Japan, Malaysia,
Korea, Singapore, UK) or are developing the regulations or guide-
lines for evaluating SBPs (e.g. Brazil, Cuba, Thailand). Meanwhile,
instead of speciﬁed regulations for SBPs, China and India have
abbreviated pathways to license non-innovator products (i.e.
products which do not include a new biological entity) which are
copies of innovator products that are licensed in various countries
and have a long and established history of good efﬁcacy and safety
[1]. In the case of Korea, there is also an abbreviated pathway, but
this pathway is distinct from the SBP pathway. More importantly,
the products licensed through this abbreviated pathway are not
called SBPs.
3.2. Terminology (answer 2)
Diverse terminology has been used for SBPs, such as ‘subsequent
entry biologics’ (Canada), ‘biosimilars’ (Malaysia, Korea), similar
biological (biosimilar) products (Singapore), similar biological
medicinal products (UK), and ‘follow-on’ biologics (Japan) [2e6]. In
Brazil and Cuba, SBPs are categorized into ‘biological products’
(Brazil) or ‘known biological products’ (Cuba) in their respective
draft new regulations, whereas innovator products are called ‘new
biological products’ (Brazil) or ‘biological products’ (Cuba) [7].
Unofﬁcially (i.e. not deﬁned in their regulations) but commonly
used terms are ‘biogeneric products’ (India), ‘biosimilars’(China)
and ‘follow-on biotherapeutic products’ (China) for products which
have been licensed through their abbreviated pathways.
3.3. Current status of licensing SBPs (answer 3)
Fourteen products are available as similar biological medicinal
products in EU (Table 1). Using the biosimilar pathway described in
their respective guidelines, Omnitrope has been approved in 2009
in Canada, Japan (named Somatropin BS s.c. "Sandoz") and
Singapore (named Scitropin A). Japan has also approved another
SBP Epoetin alfa BS "JCR" in 2010.
3.4. RBP issues (answer 4)
Evidence from the survey showed that all national regulatory
authorities require the use of nationally licensed RBPs in principle,
but some of the countries have a list of ‘reference countries/authorities’ as an additional criteria for acceptability of using RBPs
from other countries. The manufacturers in the countries may use
the RBPs from one of the listed reference countries or the RBPs that
have been approved by one of the listed reference authorities. The
examples of ‘reference countries/authorities’ in each country are
listed in Table 2. Meanwhile, in the case of Canada, the RBPs should
be authorized for sale and marketed in the country, but the guid-
ance on use of a ‘non-Canadian RBP’ is also stated in their guide-
lines. For example, products which are widely marketed in the
countries which formally adopt International Conference on
Harmonization (ICH) guidelines can be potentially used, if sufﬁcient
information on the products can be provided (Table 2).3.5. Comparability exercise (answer 5)
In principle, all countries that have issued or are developing
regulations for evaluating SBPs require comparability exercises for
quality, non-clinical, and clinical evaluation with the exceptions
given below. In Cuba, the clinical data derived in a non-comparative
manner (i.e. no head-to-head comparison) are acceptable for
licensure of ‘known biological products’ of monoclonal antibody
products. In Brazil, SBPs can be categorized as ‘biological products’
that are licensed through a comparability pathway. However, the
requirements of a comprehensive head-to-head comparison (i.e.
‘direct comparison of the properties of the SBP with the RBP in the
same study’ [8]) from quality, through non-clinical, to clinical
aspects are not clearly stated in their regulations. China and India
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versions of innovator biological products based on abbreviated
pathways in their regulations for drugs (including biological
products). Thus, partial comparative studies at quality level have
been performed for the purpose of licensing the products, and the
comparison of clinical data with published (literature) data for
originator products has been accepted for licensure of non-
innovator products.3.6. Capacity of national regulatory authorities for evaluating SBPs
(answer 6)
The responses frommost countries speciﬁed that the regulatory
authorities have sufﬁcient experience to evaluate the dossiers for
the purpose of licensing SBPs. However, the needs for specialists in
reviewing non-clinical and clinical studies are indicated.
Exchanging experience among different jurisdictions is suggested
as one solution to ﬁll the gap in their capacities.4. Discussion
The results of the survey show that the situation in many
regions obviously conﬂicts with the principles of the WHO guide-
lines [8]. Firstly, the adoption of the generic approach used for
chemical medicines is not suitable for the licensing of SBPs, or any
other biotherapeutic products. Secondly, at the quality level, full
comparability data should be provided. Thirdly, the comparability
studies should be a head-to-head comparison at all levels. Finally, it
is clearly noted that the products that are not shown to be similar to
the originator products as indicated in the Guidelines should
neither be described as "similar" nor called SBPs. Thus, three main
challenges arise from the survey: a) the appropriate comparability
studies have not been recommended by regulators in some coun-
tries; b) the products have been inappropriately called ‘biosimilars’
without conducting comparability studies for their approval; and c)
the term of ‘biogeneric’ products is still prevalent and used along
with inappropriate use of the term ‘biosimilar’ in some countries.5. Conclusion
The conclusion of the survey was that the situations in different
countries in terms of regulatory expectations for licensing of SBPs
in August 2010 were highly diverse. Also, the products that cannot
be deﬁned as SBPs as per the WHO Guidelines are mislabeled or
misleadingly referred to as ‘biosimilars’ in some countries. Even
after a regulatory framework is in place, the diversities among
classes of biotherapeutic products may require a ﬂexible approach.
Thus, the diversities in regulatory frameworks and use of the term
‘similar’ without appropriate comparability studies are the major
causes of confusion, and present a challenge for development,
licensure, and future use of SBPs.Disclaimer
The author is a staff member of the World Health Organization.
The author alone is responsible for the views expressed in this
publication and they do not necessarily represent the decisions,
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The author has disclosed no potential conﬂicts of interests.Appendix. Questionnaire concerning the evaluation of SBPs
for the purpose of licensing
1. Legislative basis.
Drugs Biologicals/ SBPsBiotherapeuticsTitle of law/act/guidelines (year of legislation)
Brief summary of differences from each othera. Biotherapeuticshavebeen licensedunder the regulations for
1) Drugs
2) Biologicals
3) Themselves
b. If your country does not have the regulation for bio-
therapeutics yet, is there any plan to set up?
c. If the regulation for SBPs already exist in your country,
please specify the guidelines that should be followed:
d. After introducing WHO guidelines on evaluating SBPs, do
you plan to implement these into your national regulations?
e. If so, when and how?
2. Terminology
a. What is the deﬁnition of "biotherapeutic products" in your
country?
b. If another term is used, such as biotechnological products,
biopharmaceutical product, protein products, biologicals,
please provide the deﬁnition as stated in your regulation:
c. SBPs stand for ‘Similar Biotherapeutic Products’ in theWHO
guidelines. What term is used for SBPs in your national
regulation?
1) Similar biotherapeutic products
2) Similar biological medicinal products
3) Follow-on protein products
4) Subsequent entry biologics
5) Biosimilars
6) Biogeneric products
7) Others:
3. Current status for licensing SBPs
* Any biologicals of similar versions; the different term may be
used in your country
a. List all products (i.e. name, the year of licensing) that have
been licensed on the basis of demonstrated similarities to
RBPs (head-to-head comparisons in quality, non-clinical
and clinical evaluation):
b. If the similaritieswereproved throughdifferent approaches,
please specify what the basis is for licensing?
4. RBPs (originator products as comparators)
a. Term for comparators in your regulation:
b. Deﬁnition:
c. Criteria to choose RBPs:
d. Acceptability of licensed products from foreign countries:
e. If the products which have not been licensed in your
country are acceptable as RBPs, please specify the rationale
of using:
f. Have any issues been raised in choosing RBPs?
5. Comparability exercise.
In quality In non-clinical In clinical
studies studies studiesComparative data
*Non-comparative data
Differences from the Guidelines*In the case of any non-comparative data were accepted.
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1) Selected criteria:
2) Examples of reducing quality data in licensing:
3) Have you experienced any difﬁculties related to meth-
odological issues, e.g. choosing different methods or
speciﬁcations from ones used for originator products,
interpreting results, using the reference materials (WHO
international standards or referencematerials, or national
standards) for potency and immunogenicity test?
b. In non-clinical study
1) Necessary data:
2) Any exception to reduce the data set in the evaluation
based on products or product classes:
3) How were the relevant animal models and the period for
test chosen?
4) Have you ever experienced any lessons or challenges in
reviewing the data?
c. In clinical studies
1) Designs: In particular, if there was experience with
licensing of SBPs (any similar versions of already licensed
biologicals) based on non-inferiority trials, please explain
it.
2) Experience of statistically superior efﬁcacy: If so, how did
the result show clinically relevant or not?
3) Select endpoints: Please provide the information in
tabulated forms, based on each product which has been
licensed. Refer the example below.
Product categories Product name Manufacturer EndpointsPrimary SecondaryRBP Somatropin Genotropin Pﬁzer
SBP Omnitrope Sandoz6. NRAs’ experience
a. Do you think your NRA has sufﬁcient experience and
expertise for evaluating each part of SBPs licensing dossiers
below?
1) Quality:
2) Non-clinical:
3) Clinical:
b. If not, how do you plan to proceed with the regulatory
overview of SBPs?
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